Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.60 |
---|---|
High | 18.60 |
Low | 18.60 |
Bid | 19.00 |
Offer | 19.10 |
Previous close | 18.60 |
Average volume | 66.67 |
---|---|
Shares outstanding | 5.28m |
Free float | 3.01m |
P/E (TTM) | -- |
Market cap | 104.03m USD |
EPS (TTM) | -1.99 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 07:02 GMT.
More ▼
Announcements
- Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
- Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
- Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
- Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
- Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
- Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
- Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
- Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
- Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
- Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
More ▼